Navigation Links
Once-daily Nevirapine Has More Side-effects Than Twice-daily Dose

arable between the once-daily and twice-daily treated patients.

However, they also found that there was a trend for patients who were taking the drug once daily to be more likely to change therapy than those who were taking a twice-daily dose of nevirapine (29% versus 22%). They suggest that this could be because of a greater incidence of side-effects.

More patients experienced liver abnormalities in the once-daily group compared with twice-daily nevirapine (14% versus 8%; p=0.036). Also more patients in the once-daily group temporarily or permanently discontinued therapy because of rash (12% versus 7%).

Other smaller clinical trials were considered in the review. Each found that there was no statistically significant difference in the efficacy of once-daily and twice-daily nevirapine. In two of these studies there were also no differences in the frequency of adverse events between once and twice-daily regimens. A further study did, however, highlight a difference in frequency of adverse events between once- and twice-daily dosing of nevirapine.

This study involved 196 patients to investigate the safety and efficacy of switching from various twice-daily regimens (with or without nevirapine) to once-daily nevirapine (400mg), ddI (400mg) and tenofovir (300mg). In this study, adverse events leading to treatment discontinuation were more common in the once-daily group. After 48 weeks, three patients (4%) who continued twice-daily dosing stopped therapy versus twelve individuals (14%) who switched to once-daily dosing. The reasons for treatment discontinuation were: five cases of nevirapine-related hepatitis, two of acute pancreatitis, two of skin rash, two of dry mouth and one of peripheral neuropathy.

“Unfortunately, when compared with twice-daily dosing, antiretroviral regimens in which nevirapine is dosed at 400mg once daily immediately after a 2-week lead-in period are associated with an increased risk
'"/>




Page: 1 2 3

Related medicine news :

1. New Dietary Approach To Manage Kidney Stones
2. Approaching through Telemedicine benefits patients
3. Gel Offers A More Targeted Approach
4. New Cost Effective Approach To Promote Sun Protection
5. Treatment Of Brain Aneurysms By A New Non-Surgical Approach
6. A New Approach In Treatment Neurogenic Detrusor Overactivity In Children
7. A New Diagnostic Approach To Pediatric Interstitial Lung Disease
8. Lazy Eye Can Be Effectively Treated By New Approach
9. Novel Approach to Identify Protein Links with Genetic Disorder
10. NHS To Be Reformed By Using A Hybrid Approach
11. Two-In One Approach To Prevent Incontinence After Prolapse Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Once daily Nevirapine Has More Side effects Than Twice daily Dose

(Date:8/2/2014)... According to the Girl Gets Ring System review ... for women. The book consists of dating tips and tricks ... book also teaches women how to deal with relationship ... its review that this book is divided into 10 chapters ... Story? ,     Chapter 2 – How A Traffic Light ...
(Date:8/2/2014)... On July 21, 2014, the Johns Hopkins Health ... settle the class action lawsuit filed October 24, ... 24-C-13-001041 MM, on behalf of thousands of women who allegedly ... According to The Baltimore Sun , the $190 ... a physician accused of sexual misconduct. , An investigation prompted ...
(Date:8/1/2014)... The successful development of C60F projects is of ... Automobile Co.,LTD. As early as the very beginning of ... excellent team to develop a comprehensive plan to carry ... The company’s vice president Liming Yang and some of ... the specific arrangement and the supervision of the project ...
(Date:8/1/2014)... of Medicine in St. Louis helps explain why brain ... more harmful than similar tumors in females. For example, ... twice as often in males, who suffer greater cognitive ... , The researchers found that retinoblastoma protein (RB), a ... active in male brain cells than in female brain ...
(Date:8/1/2014)... (HealthDay News) -- The U.S. Food and Drug Administration ... Jardiance, to help fight type 2 diabetes. ... existing treatment regimens to control blood sugar levels in ... of the Office of Drug Evaluation II in the ... an agency statement. The FDA also recommended that ...
Breaking Medicine News(10 mins):Health News:Girl Gets Ring System Review Exposes Jonathan Green's Dating Guide For Women – Vkool.com 2Health News:Girl Gets Ring System Review Exposes Jonathan Green's Dating Guide For Women – Vkool.com 3Health News:Baltimore Lawyer Steven H. Heisler Urges Victims of OB/GYN Misconduct to Speak Out 2Health News:Baltimore Lawyer Steven H. Heisler Urges Victims of OB/GYN Misconduct to Speak Out 3Health News:FODAY Automobile Company Is Now Working On The C60F FODAY Project 2Health News:Study reveals one reason brain tumors are more common in men 2Health News:FDA Approves New Type 2 Diabetes Drug 2
... House ceremony next month, Thomas L. Kash, PhD, assistant professor ... for Alcohol Studies at the University of North Carolina at ... Career Award for Scientists and Engineers (PECASE). , This is ... science and engineering professionals in the early stages of their ...
... in the October 2011 issue of The FASEB ... "healthy" ingredient in red wine, stops breast cancer cells ... This discovery, made by a team of American and ... is able to counteract the malignant progression since it ...
... By Serena Gordon HealthDay Reporter , WEDNESDAY, Sept. 28 ... advanced Alzheimer,s or other form of severe dementia will be shuttled ... months of life, a new U.S. study shows. The ... Depending on where a patient lives, as many as ...
... the British Journal of Sports Medicine * highlights the injury ... chance of a school player suffering an injury during a single ... research, could be as high as 90 per cent. The ... City University say there is an urgent need to inform children, ...
... with dementia can still make decisions in their everyday lives ... as their condition advances. This is one of the preliminary ... and Social Research Council (ESRC) into how married couples living ... study is investigating how couples make decisions over issues such ...
... dose of the hallucinogen psilocybin, the active ingredient in ... measureable personality change lasting at least a year in ... new study, according to the Johns Hopkins researchers who ... part of the personality known as openness, which includes ...
Cached Medicine News:Health News:UNC researcher to receive highest US honor for early career science professionals 2Health News:End-Stage Alzheimer's Patients Often Hospitalized Unnecessarily 2Health News:End-Stage Alzheimer's Patients Often Hospitalized Unnecessarily 3Health News:Academic issues warning on schoolboy rugby 2Health News:Living with dementia and making decisions 2Health News:Single dose of hallucinogen may create lasting personality change 2Health News:Single dose of hallucinogen may create lasting personality change 3
(Date:7/31/2014)... , July 31, 2014  Sorrento Therapeutics, Inc. (NASDAQ: ... Mr. Amar Singh , Chief Business Officer and Executive ... natural causes on July 30. "Sorrento is deeply ... and colleague. Our immediate thoughts go to Amar,s family and ... Chief Executive Officer. Mr. Singh joined Sorrento ...
(Date:7/31/2014)... Diabetes Care®, Inc. (NASDAQ: TNDM ), a medical ... reported its financial results for the quarter ended June 30, ... 2014 to the same period of 2013: , Sales ... , t:slim Pump shipments grew 64 percent to 2,235 pumps ... June 30, 2014 to the same period of 2013: ...
(Date:7/31/2014)... 31, 2014 Nektar Therapeutics (Nasdaq: NKTR ... ended June 30, 2014. Cash and investments ... as compared to $309.1 million at March 31, 2014."The second ... as we look forward to significant milestones for a number ... and Chief Executive Officer of Nektar. "The first of these ...
Breaking Medicine Technology:Sorrento Announces the Unexpected Death of its Chief Business Officer 2Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 2Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 3Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 4Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 5Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 6Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 2Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 3Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 4Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 5Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 6Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 7Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 8Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 9Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 10Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 11Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 12Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 13Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 14
... Invuity, a leading developer of state-of-the-art illuminated surgical ... at the American College of Surgeons, 97th Annual ... specifically for breast mastectomies, lumpectomies, sentinel node biopsies ... proprietary Eigr ™ (pronounced eye-gr) illumination technology ...
... Generex Biotechnology Corporation (OTCBB: GNBT) ( www.generex.com ) announced ... conference call for late November.  The purpose of the ... (i) the status of the Company,s efforts in respect ... subsidiary, Antigen Express, Inc. ( www.antigenexpress.com ), (ii) financing ...
Cached Medicine Technology:Invuity Introduces Advanced Illuminated Surgical System for Breast Procedures 2Invuity Introduces Advanced Illuminated Surgical System for Breast Procedures 3Generex Announces Investor Update Conference Call Planned for Late November 2Generex Announces Investor Update Conference Call Planned for Late November 3
... Oncotype DX™ is a diagnostic assay that ... in women with newly diagnosed, early stage ... disease recurrence, Oncotype DX also assesses the ... assay performed using formalin-fixed, paraffin-embedded tumor ...
... HER2 FISH pharmDx Kit is a direct ... to quantitatively determine HER2 gene amplification in ... amplification is determined from the ratio between ... of the HER2 gene probe (red signals) ...
... age of 3 can choose either the PARI ... design principle applies to both:, ,Maximize aerosol ... output when the patient exhales using two one-way ... leave the nebulizer. The result is a high ...
... breakthrough continuous low-flow nebulizer performance. Patented ... technology allows for optimal medication and ... Heliox). OMNI~NEB takes on severe asthma, ... and critical care situations. Configure with ...
Medicine Products: